Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion

RetatrutideEBGLYSSNeutral

AI Analysis

Summary

Analyst rates Eli Lilly as a 'Strong Buy' based on Retatrutide obesity drug and EBGLYSS maintenance label expansion. No specific clinical or regulatory data provided in the article.

Importance:2/10

Sentiment:

0.00

obesitydrug_label_expansionanalyst_recommendation

Related Companies

$LLY

Read the original article

Published by Seeking Alpha Healthcare on August 7, 2026 10:29 PM

Read Original